Business
Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotec...
About this update from Prime Drink Group Corp
[{"type":"text","content":"Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy -- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 --\n\n\n\n CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, its Prime Editor for the treatment of H1069Q-driven Wilson’s Disease, in the first half of 2026, with initial clinical data expected in 2027.\n \n\n Presentations will feature members of the Company’s management team, as well as Dr. Michael Schilsky, Professor of Medicine at Yale School of Medicine and Medical Director of the Adult Liver Transplant program at Yale New Haven Transplantation Center, and will highlight:\n \n\n\n Prime Medicine’s strategy to efficiently develop Prime Editors for genetic liver diseases.\n \n\n The Wilson’s Disease treatment landscape, patient experience and global market opportunity, for which there is no curative therapy available and current standard-of-care is limited by compliance, cost and tolerability.\n \n\n The potential for Prime Editing to provide a durable cure for Wilson’s Disease by precisely and permanently genetic cause(s) of Wilson’s Disease.\n \n\n Prime Medicine’s plans to leverage the modularity of its Prime Editing platform to accelerate the development of multiple Prime Editors for Wilson’s Disease and beyond.\n \n\n\n\n\n The event will be webcast live and those who intend to join can pre-register for the webcast\n \n here\n \n .\n \n\n The live webcast and supporting presentation materials will be available on the \"News & Events\" section of Prime Medicine’s Investor Relations webpage at investors.primemedicine.com. An archived replay will also be available.\n \n\n\n About Prime Medicine\n \n\n Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company ...